Skip Nav Destination
Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience
Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells
Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide
Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation
Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT
Issue Archive
Table of Contents
BLOOD ADVANCES TALK
EXCEPTIONAL CASE REPORT
Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience
Clinical Trials & Observations
STIMULUS REPORT
Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia
Clinical Trials & Observations
Karine Darbinyan,Aditi Shastri,Anjali Budhathoki,Daniel Helbig,Rose Snyder,Kith Pradhan,Junaid Saleh-Esa,Noah S. Kornblum,Adam F. Binder,Swati Goel,Murali Janakiram,Olga Derman,Kira Gritsman,Ulrich Steidl,Ira Braunschweig,Amit Verma,Ioannis Mantzaris
REVIEW ARTICLES
CLINICAL TRIALS AND OBSERVATIONS
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study
Clinical Trials & Observations
Marianna Thordardottir,Ebba K. Lindqvist,Sigrun H. Lund,Rene Costello,Debra Burton,Neha Korde,Sham Mailankody,Gudny Eiriksdottir,Lenore J. Launer,Vilmundur Gudnason,Tamara B. Harris,Ola Landgren,Sigurdur Y. Kristinsson
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells
Clinical Trials & Observations
Barbara Withers,Emily Blyth,Leighton E. Clancy,Agnes Yong,Chris Fraser,Jane Burgess,Renee Simms,Rebecca Brown,David Kliman,Ming-Celine Dubosq,David Bishop,Gaurav Sutrave,Chun Kei Kris Ma,Peter J. Shaw,Kenneth P. Micklethwaite,David J. Gottlieb
HEALTH SERVICES AND OUTCOMES
HEMATOPOIESIS AND STEM CELLS
A knock-in mouse strain facilitates dynamic tracking and enrichment of MEIS1
Ping Xiang,Wei Wei,Nicole Hofs,Jack Clemans-Gibbon,Tobias Maetzig,Courteney K. Lai,Ishpreet Dhillon,Christopher May,Jens Ruschmann,Edith Schneider,Patricia Rosten,Kaiji Hu,Florian Kuchenbauer,Pamela A. Hoodless,R. Keith Humphries
IMMUNOBIOLOGY AND IMMUNOTHERAPY
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects
Hirofumi Tenshin,Jumpei Teramachi,Asuka Oda,Ryota Amachi,Masahiro Hiasa,Ariunzaya Bat-Erdene,Keiichiro Watanabe,Masami Iwasa,Takeshi Harada,Shiro Fujii,Kumiko Kagawa,Kimiko Sogabe,Shingen Nakamura,Hirokazu Miki,Kiyoe Kurahashi,Sumiko Yoshida,Kenichi Aihara,Itsuro Endo,Eiji Tanaka,Toshio Matsumoto,Masahiro Abe
LYMPHOID NEOPLASIA
BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia
Yo-Ting Tsai,Aparna Lakshmanan,Amy Lehman,Bonnie K. Harrington,Fabienne McClanahan Lucas,Minh Tran,Ellen J. Sass,Meixiao Long,Alan D. Flechtner,Florinda Jaynes,Krista La Perle,Vincenzo Coppola,Gerard Lozanski,Natarajan Muthusamy,John C. Byrd,Michael R. Grever,David M. Lucas
TRANSPLANTATION
Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates
Jean Kwun,Christopher Burghuber,Miriam Manook,Brian Ezekian,Jaeberm Park,Janghoon Yoon,John S. Yi,Neal Iwakoshi,Adriana Gibby,Jung Joo Hong,Alton B. Farris,Allan D. Kirk,Stuart J. Knechtle
Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide
Clinical Trials & Observations
Franco Aversa,Esther Bachar-Lustig,Noga Or-Geva,Lucia Prezioso,Sabrina Bonomini,Ilenia Manfra,Alessandro Monti,Chiara Schifano,Yael Zlotnikov-Klionsky,Massimo F. Martelli,Gabriella Sammarelli,Maria Sassi,Maurizio Soli,Silvia Giuliodori,Magda Benecchi,Nicola Giuliani,Frank Lohr,Silvia Pratissoli,Yair Reisner
Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation
Clinical Trials & Observations
Mieke Aldenhoven,Brigitte T. A. van den Broek,Robert F. Wynn,Anne O’Meara,Paul Veys,Attilio Rovelli,Simon A. Jones,Rossella Parini,Peter M. van Hasselt,Marleen Renard,Victoria Bordon,Tom J. de Koning,Jaap Jan Boelens
Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study
Clinical Trials & Observations
Hesham M. Eissa,Lu Lu,Malek Baassiri,Nickhill Bhakta,Matthew J. Ehrhardt,Brandon M. Triplett,Daniel M. Green,Daniel A. Mulrooney,Leslie L. Robison,Melissa M. Hudson,Kirsten K. Ness
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma
Clinical Trials & Observations
Damian J. Green,David G. Maloney,Barry E. Storer,Brenda M. Sandmaier,Leona A. Holmberg,Pamela S. Becker,Min Fang,Paul J. Martin,George E. Georges,Michelle E. Bouvier,Rainer Storb,Marco Mielcarek
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT
Clinical Trials & Observations
Vincent T. Ho,Haesook T. Kim,Natalie Bavli,Martin Mihm,Olga Pozdnyakova,Matthias Piesche,Heather Daley,Carol Reynolds,Nicholas C. Souders,Corey Cutler,John Koreth,Edwin P. Alyea,Joseph H. Antin,Jerome Ritz,Glenn Dranoff,Robert J. Soiffer
-
Cover Image
Cover Image
COVER FIGURE
Peripheral lymph nodes biopsied before and after desensitization with dual targeting. Dual targeting desensitization treatment (bortezomib, belatacept, and anti-CD40 monoclonal antibody) significantly reduced germinal centers in sensitized nonhuman primates. See the article by Kwun et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals